Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. Natesan D, et al. Among authors: koshkin vs. Front Oncol. 2022 Mar 7;12:816706. doi: 10.3389/fonc.2022.816706. eCollection 2022. Front Oncol. 2022. PMID: 35321431 Free PMC article.
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. Kwon DH, et al. Among authors: koshkin vs. Urol Oncol. 2023 Mar;41(3):145.e7-145.e15. doi: 10.1016/j.urolonc.2022.10.025. Epub 2022 Nov 24. Urol Oncol. 2023. PMID: 36435709 Free article.
Editorial: Radical cystectomy in bladder cancer patients.
Koshkin VS, Almassi N, Aragon-Ching JB. Koshkin VS, et al. Front Oncol. 2022 Dec 19;12:1113112. doi: 10.3389/fonc.2022.1113112. eCollection 2022. Front Oncol. 2022. PMID: 36601472 Free PMC article. No abstract available.
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Jindal T, et al. Among authors: koshkin vs. Front Oncol. 2023 Apr 5;13:1161089. doi: 10.3389/fonc.2023.1161089. eCollection 2023. Front Oncol. 2023. PMID: 37091148 Free PMC article.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Fizazi K, et al. Among authors: koshkin vs. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. Lancet Oncol. 2023. PMID: 37269841 Free PMC article. Clinical Trial.
Editorial: Methods in genitourinary oncology.
Jang A, Sella A, Nassar AH, Koshkin VS. Jang A, et al. Among authors: koshkin vs. Front Oncol. 2023 Aug 24;13:1274264. doi: 10.3389/fonc.2023.1274264. eCollection 2023. Front Oncol. 2023. PMID: 37692849 Free PMC article. No abstract available.
98 results